Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.54 |
| ▸ | GRM5 | P41594 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13338101 | 0.90 | MAOB (0.59) | MAOBMAOATSHR | |
| SCHEMBL10576255 | 0.85 | TP53 (0.53) | MAOBLMNAMAPK1MAOATSHR | |
| SCHEMBL31404220 | 0.84 | ALDH1A1 (0.50) | MAOBMAPK1MAOATSHR | |
| 1,3-Dimethoxybenzene SCHEMBL27963601 | 0.82 | MAOB (0.50) | MAOBLMNAMAPK1APPTSHR | |
| SCHEMBL8195567 | 0.81 | MAOB (0.53) | MAOBGRM5LMNAMAPK1APP | |
| SCHEMBL4815490 | 0.81 | MAOB (0.52) | MAOBMAOATSHR | |
| SCHEMBL5254418 | 0.81 | LMNA (0.56) | MAOBGRM5LMNAMAPK1APP | |
| SCHEMBL20540824 | 0.80 | MAOB (0.48) | MAOBMAOATSHR | |
| SCHEMBL5981846 | 0.79 | CA12 (0.53) | MAOBGRM5MAOA | |
| SCHEMBL11129665 | 0.79 | MAOB (0.56) | MAOBLMNAMAOATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4186896-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-109096212-B | Method for synthesizing 5-I-1,2, 3-triazole compound by water phase one-pot method | 河南师范大学 | 2021-07-13 | — | — | CN | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-12-04 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3145512-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015178955-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-6762178-B2 | FOR USE IN TREATMENT OF DISEASE CONDITIONS MEDIATED BY TNF-ALPHA, SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE, DEGENERATIVE CARTILAGE LOSS | WYETH HOLDINGS CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040132784-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-08 | — | — | US | disclosed |
| US-6723745-B2 | PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20030236297-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | AMERICAN CYANAMID COMPANY (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1144369-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6277885-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY | 2001-08-21 | — | — | US | disclosed |
| WO-2000044710-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-4867915-A | LIPOXYGENASE INHIBITORS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236297-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | MAOB 1891/4885GRM5 982/4885LMNA 3703/4885 |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | BTK, BCL9, LCK | MAOB 1675/4885GRM5 2483/4885LMNA 4126/4885 |
| US-20040132784-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | MAOB 1891/4885GRM5 982/4885LMNA 3703/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | MAOB 2789/4885GRM5 4000/4885LMNA 4323/4885 |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | BTK, BCL9, LCK | MAOB 1675/4885GRM5 2483/4885LMNA 4126/4885 |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | PTPRF, PTPRCAP, PTPRJ | MAOB 3515/4885GRM5 2294/4885LMNA 4731/4885 |
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | PTDSS1, SAT1, TNF | MAOB 3438/4885GRM5 3712/4885LMNA 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.